ArticleLung India : official organ of Indian Chest Society2026
Fragile immunity, fatal foe: A cluster of Pneumocystis jirovecii pneumonia cases in children with haematological malignancies on chemotherapy.
Article in Lung India : official organ of Indian Chest Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPneumocystis jirovecii causes a potentially fatal interstitial pneumonia, especially in immunosuppressed hosts. It was the most common cause of death in children with leukaemia, before the introduction of prophylaxis.
aimsIn this study, we evaluated the clinical and demographic characteristics of proven PJP cases in children with haematological malignancy on chemotherapy. The study also determined the association of PJP characteristics with various phases of chemotherapy.
methodsThis was a retrospective study conducted at a tertiary care teaching hospital in Delhi. Cases included 13 children less than 12 years of age with leukaemia on chemotherapy with proven PJP diagnosis, according to the EORTC/MSGERC guidelines. For microbiological diagnosis, direct immunofluorescence was performed using the Merifluor® Pneumocystis kit manufactured by Meridian Bioscience Inc.
resultsB-cell acute lymphoblastic leukaemia was the most common haematological malignancy seen in these cases. Most of the PJP cases were seen in the maintenance phase of chemotherapy. The clinical profile of the PJP cases includes fever, cough, cytopenia, hypoxaemia, coryza, dyspnoea, and hepatitis. The radiological findings of the PJP cases include bilateral diffuse ground-glass opacification, perihilar infiltrates, and unilateral infiltrates. The mortality rate of the PJP cases was 15.4%.
conclusionsPneumocystis jirovecii causes a potentially life-threatening pneumonia, especially in immunocompromised individuals such as children with leukaemia on chemotherapy. PJP presents more severely with rapid progression and higher mortality rate in children with leukaemia than in HIV-positive cases. Therefore, early diagnosis and prompt treatment initiation is paramount in reducing morbidity and mortality in these cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.